| Product Code: ETC7916464 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
In 2024, Latvia saw significant import shipments of the netupitant palonosetron FDC, with top exporters being Lithuania, Netherlands, Switzerland, Poland, and Germany. Despite the strong growth with a CAGR of 8.6% from 2020 to 2024, the market remained moderately concentrated with a low Herfindahl-Hirschman Index (HHI). The growth rate of 7.03% from 2023 to 2024 indicates a steady expansion in the import market for this pharmaceutical combination in Latvia. This data suggests a positive outlook for the continued importation and availability of netupitant palonosetron FDC in the country.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Latvia Netupitant Palonosetron FDC Market Overview |
3.1 Latvia Country Macro Economic Indicators |
3.2 Latvia Netupitant Palonosetron FDC Market Revenues & Volume, 2021 & 2031F |
3.3 Latvia Netupitant Palonosetron FDC Market - Industry Life Cycle |
3.4 Latvia Netupitant Palonosetron FDC Market - Porter's Five Forces |
3.5 Latvia Netupitant Palonosetron FDC Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Latvia Netupitant Palonosetron FDC Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 Latvia Netupitant Palonosetron FDC Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chemotherapy-induced nausea and vomiting (CINV) in Latvia |
4.2.2 Growing awareness and adoption of combination therapies for CINV management |
4.2.3 Favorable government regulations and policies supporting the use of netupitant palonosetron FDC |
4.3 Market Restraints |
4.3.1 High costs associated with netupitant palonosetron FDC treatment |
4.3.2 Limited availability and accessibility of specialized healthcare facilities for administering the treatment |
4.3.3 Competition from alternative treatment options for CINV |
5 Latvia Netupitant Palonosetron FDC Market Trends |
6 Latvia Netupitant Palonosetron FDC Market, By Types |
6.1 Latvia Netupitant Palonosetron FDC Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Latvia Netupitant Palonosetron FDC Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Latvia Netupitant Palonosetron FDC Market Revenues & Volume, By Flakes, 2021- 2031F |
6.1.4 Latvia Netupitant Palonosetron FDC Market Revenues & Volume, By Capsules, 2021- 2031F |
6.1.5 Latvia Netupitant Palonosetron FDC Market Revenues & Volume, By Other, 2021- 2031F |
6.2 Latvia Netupitant Palonosetron FDC Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Latvia Netupitant Palonosetron FDC Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.2.3 Latvia Netupitant Palonosetron FDC Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
7 Latvia Netupitant Palonosetron FDC Market Import-Export Trade Statistics |
7.1 Latvia Netupitant Palonosetron FDC Market Export to Major Countries |
7.2 Latvia Netupitant Palonosetron FDC Market Imports from Major Countries |
8 Latvia Netupitant Palonosetron FDC Market Key Performance Indicators |
8.1 Patient adherence rates to netupitant palonosetron FDC regimen |
8.2 Number of healthcare professionals trained in administering the treatment |
8.3 Rate of adverse events reported post-treatment with netupitant palonosetron FDC |
9 Latvia Netupitant Palonosetron FDC Market - Opportunity Assessment |
9.1 Latvia Netupitant Palonosetron FDC Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Latvia Netupitant Palonosetron FDC Market Opportunity Assessment, By Application, 2021 & 2031F |
10 Latvia Netupitant Palonosetron FDC Market - Competitive Landscape |
10.1 Latvia Netupitant Palonosetron FDC Market Revenue Share, By Companies, 2024 |
10.2 Latvia Netupitant Palonosetron FDC Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |